Key result
A totally micro-invasive strategy of PCI followed by NeoChord mitral repair yielded 100% survival at 1 year, with only one reoperation due to late NeoChord failure among 16 followed patients.
Why the study?
To assess early outcomes of a totally micro-invasive strategy combining PCI followed by transapical off-pump NeoChord mitral repair in patients with concomitant CAD and degenerative MR.
Is a totally micro-invasive strategy of PCI followed by transapical off-pump NeoChord mitral repair safe and effective in patients with concomitant CAD and degenerative MR?
Observational (n=17)
No
Is a totally micro-invasive strategy of PCI followed by transapical off-pump NeoChord mitral repair safe and effective in patients with concomitant CAD and degenerative MR?
Answers are grounded in this paper and cite their sources.
A totally micro-invasive strategy combining PCI and transapical off-pump NeoChord mitral repair appears safe and feasible in selected patients with concomitant CAD and degenerative MR.
BACKGROUND AND AIM OF THE STUDY: Micro-invasive cardiac surgery identifies procedures performed off-pump, on beating heart. Aim of this single-center retrospective study was to assess early outcomes of a totally micro-invasive strategy (percutaneous coronary intervention-PCI-followed by transapical off-pump NeoChord mitral repair) in patients with concomitant coronary artery disease (CAD) and degenerative mitral regurgitation (MR). METHODS: We analyzed early and 1-year follow-up data of patients who underwent a NeoChord procedure between November 2013 and May 2020, and preceded by PCI. Outcomes were defined according to Mitral Valve Academic Research Consortium (MVARC) definitions. RESULTS: Among 220 patients who underwent NeoChord repair in the study period, 17 (7.7%) underwent PCI previously. CAD was an accidental finding during preoperative mitral evaluation in nine patients (52.9%; Group 1; with PCI occurring 2 months before NeoChord, interquartile range [IQR] = 1.0-2.7), while it was part of the past medical history in the remaining eight patients (47.1%; Group 2; with PCI occurring 30 months before NeoChord, IQR = 24.5-64.0). Twelve patients (70.6%) presented single-vessel disease, two patients (11.8%) triple-vessel disease. No surgical revisions for bleeding were required after NeoChord. At 1-year follow-up (n = 16), all patients were alive and did not experience major adverse events except for one reoperation due to late NeoChord failure. None required additional PCI. CONCLUSION: In our experience, PCI before NeoChord seems safe and effective, and performing PCI before NeoChord might not affect outcomes. A totally micro-invasive strategy in selected patients suffering from MR and CAD should be considered as a reasonable alternative to conventional surgery.
No takes yet. Share an insight, caveat, or question.
Pradegan et al. (2021) conducted an observational in Concomitant coronary artery disease (CAD) and degenerative mitral regurgitation (MR) (n=17). Percutaneous coronary intervention (PCI) followed by NeoChord mitral repair was evaluated on Early and 1-year follow-up outcomes according to Mitral Valve Academic Research Consortium (MVARC) definitions. A totally micro-invasive strategy of PCI followed by NeoChord mitral repair yielded 100% survival at 1 year, with only one reoperation due to late NeoChord failure among 16 followed patients.
Synapse has enriched 10 related papers. Consider them for comparative context: